The directors founded Oxygen Healthcare (O2H) in May 2003 and provided Strategic Consulting, Investment Advisory & Business Development to a range of clients operating within the field of discovery and biotechnology such as Adprotech (now Inflazyme), Arakis, Cambridge Biotechnology (now part of Biovitrum), UCL Biomedica, and Amicus Therapeutics. The consulting projects have covered strategic planning, licensing, spin-outs, fund-raising, technology assessments, market assessments, business plan development, clinical trials modelling, JV structuring, investment evaluation, partnership development, business development and business modelling. O2H also began providing support to companies interested in carrying our research and operations in India.

Following discussions with our consulting clients it was clear that constraints in research capacity, expertise and budget were limiting growth prospects for shareholders. At the same time it was clear that India was emerging as a global destination for research. Further detailed discussions continued with leading scientists from the Cambridge cluster in order that the needs of world class research companies were carefully understood in a globalised economy.

O2H now provides a world class discovery service from India to bring high quality science to the research companies based in EU, USA and Japan and have achieved a significant degree of repeat custom. The contract chemistry research facility in India was launched in April 2005. O2H’s UK office is based in the Cambridge Science Park, UK at the heart of Europe’s leading biotechnology cluster.